Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Viewpoints - The new materials sector is a crucial direction for the future development of the chemical industry, currently experiencing rapid downstream demand growth. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational nature of the new materials industry for other sectors [4][15]. Summary by Relevant Sections 1. Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [5]. - The global semiconductor manufacturing industry is projected to maintain strong growth, with capacity expected to grow at a CAGR of 7% from the end of 2024 to 2028, reaching a record monthly output of 11.1 million wafers. Advanced process capacity (7nm and below) is anticipated to increase from 850,000 wafers per month in 2024 to a historical high of 1.4 million wafers per month by 2028, representing a growth of approximately 69% and a CAGR of about 14%, which is double the industry average [6][28]. 2. Aerospace Sector - Focus on PI films, precision ceramics, and carbon fibers [7]. 3. New Energy Sector - Focus on photovoltaics, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [9]. - As of May 2025, China's cumulative installed photovoltaic capacity has surpassed 1 billion kilowatts, reaching 1.08 billion kilowatts, which is equivalent to about 48 Three Gorges power stations and accounts for 30% of the total installed capacity in China, nearly half of the global photovoltaic installed capacity [10]. 4. Biotechnology Sector - Focus on synthetic biology and scientific services [11]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorption resins, membrane materials, and biodegradable plastics [13]. Key Companies and Profit Forecasts - The report highlights several key companies with their respective stock prices and earnings per share (EPS) forecasts for 2023, 2024E, and 2025E, along with their price-to-earnings (PE) ratios and investment ratings. For example, Ruihua Tai (688323.SH) has a stock price of 14.45 with an EPS forecast of 0.29 for 2025, rated as "Increase" [17].

Core Viewpoint - The special engineering plastics industry is experiencing significant growth driven by national policies and increasing demand from high-tech sectors such as new energy vehicles, 5G communication, and aerospace. The market size in China is projected to grow from 7.2 billion yuan in 2018 to 16 billion yuan in 2024, and further to 21.2 billion yuan by 2027 [1][19]. Industry Overview - Special engineering plastics are a third generation of plastics, crucial for national economic development and high-end manufacturing upgrades. They include materials like polyimide (PI), polyamide-imide (PAI), and polyether-ether-ketone (PEEK), which exhibit high thermal stability and are used in electronics, automotive, and aerospace applications [4][19]. - The industry has evolved through four stages: the initial phase (1950-1979) focused on imports, the development phase (1980-1999) saw increased domestic production, the rapid growth phase (2000-2010) involved technological advancements, and the current mature phase (2011-present) emphasizes innovation and sustainability [6][7][8]. Market Dynamics - The domestic market for special engineering plastics is expected to grow significantly, with a compound annual growth rate (CAGR) of 14.5% for key raw materials like naphtha, which is projected to increase from 35.8 million tons in 2018 to 80.7 million tons by 2024 [12]. - The global market for special engineering plastics is also expanding, with a forecasted growth from $9.853 billion in 2018 to $15.376 billion in 2024, and expected to reach $16.493 billion by 2025 [16][19]. Key Companies - Notable companies in the industry include Kingfa Technology, Water Holdings, and Prit, which are actively involved in the research, production, and sales of special engineering plastics. These companies are focusing on innovation and expanding their market presence [2][23][24]. - Kingfa Technology reported a revenue of 59.536 billion yuan in 2024, reflecting a year-on-year growth of 26.35% [26]. Water Holdings achieved a revenue of 0.922 billion yuan, with a growth of 10.55% [28]. Development Trends - The industry is moving towards functionalization, high performance, and scalability, with a focus on developing materials that meet specific application needs in sectors like aerospace and electronics [30][31][33]. - There is a growing emphasis on sustainability, with initiatives aimed at developing recyclable materials and optimizing production processes to reduce environmental impact [35]. Application Areas - Special engineering plastics are increasingly used in high-tech applications, including aerospace components, automotive parts, and electronic devices, driven by the demand for materials that can withstand extreme conditions [13][19][30].

深圳瑞华泰薄膜科技股份有限公司 关于获得政府补助的公告 | 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-028 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 特此公告。 深圳瑞华泰薄膜科技股份有限公司董事会 2025 年 6 月 27 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得政府补助的基本情况 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）全资子公司嘉兴瑞 华泰薄膜技术有限公司于近日收到政府补助款人民币 3,189 万元，属于与资产相 关的政府补助。 二、补助的类型及对上市公司的影响 根据《企业会计准则第 16 号——政府补助》的有关规定，公司获得的上述 政府补助属于与资产相关的政府补助。上述政府补助未经审计，具体的会计处理 及对公司损益的影响最终以审计机构年度审计确认后的结果为准，敬请投资者注 意投资风险。 1 ...

Core Viewpoint - The article discusses the recent developments in the production of polyimide (PI) films in China, highlighting the investments and projects by various companies, particularly Inner Mongolia Zhongke Jiuyuan New Materials Technology Co., Ltd., which is expanding its production capacity to meet the growing demand in high-tech applications [2][4][16]. Group 1: Company Developments - Inner Mongolia Zhongke Jiuyuan has initiated a PI film production project with a total investment of 700 million yuan, planning to set up 24 production lines with an annual capacity of 3,000 tons [2]. - The company is a wholly-owned subsidiary of Zhejiang Zhongke Jiuyuan, which has signed a total investment agreement of 2.1 billion yuan for PI film production projects, including an initial phase with 24 production lines and a future phase with an additional 48 lines [4]. - Zhongke Jiuyuan has established nearly 50,000 tons of related production capacity across various provinces including Zhejiang, Anhui, Inner Mongolia, and Shanxi [4]. Group 2: Market Potential and Applications - PI films are recognized for their unique properties such as high mechanical performance, chemical resistance, flexibility, thermal stability, and electrical insulation, making them suitable for applications in flexible circuit boards, displays, and electronic devices [6]. - The demand for PI films is expected to grow significantly, particularly in the emerging 5.5G/6G technology sectors, where PI's dielectric performance can be enhanced through specific formulations [6][16]. - The global market for PI films is currently dominated by foreign companies, with major players holding approximately 80% of the high-end PI film market share [16]. Group 3: Technological Advancements - Recent advancements in domestic PI film production have led to the emergence of several companies capable of breaking the foreign monopoly, with notable examples including Zhuzhou Times New Material Technology, which has developed high-end electronic-grade PI films [8][9]. - Innovations in production processes, such as the introduction of AI algorithms for optimizing film thickness and efficiency, have been reported, enhancing production capabilities and quality [14]. - Research teams are also making strides in developing new materials, including bio-based PI materials and high thermal conductivity composites, indicating a trend towards more sustainable and high-performance products [15][13].

Group 1: Healthcare Legislation and Regulation - The draft of the Medical Security Law aims to establish a comprehensive basic medical insurance system and protect the rights of insured individuals [1] - The National Medical Products Administration (NMPA) held a meeting to enhance monitoring and management of medical device sales online, emphasizing risk governance and public safety [2] - Tianjin's health authorities issued a notice to promote the implementation of centralized procurement results, ensuring that selected drugs and consumables are procured within three months [3] Group 2: Medical Data and Technology - Hubei province launched a new feature for its medical insurance information platform to enable nationwide sharing of medical imaging data by 2026 [4] - The Gates Foundation announced a commitment to donate $1.6 billion to the Global Vaccine Alliance over the next five years, contributing to vaccine development and delivery [6] Group 3: Pharmaceutical Developments - Lizhu Group received approval for clinical trials of YJH-012 injection, a new siRNA drug aimed at long-term suppression of uric acid production [5] - Haisheng Pharmaceutical's HSK47388 tablet for autoimmune diseases has had its clinical trial application accepted by the NMPA [6] - Baiyue Shenzhou announced the clinical use of its bispecific HER2 inhibitor in China, targeting patients with HER2-positive biliary tract cancer [8] - Haichuang Pharmaceutical's new anti-cancer drug, Dihengzalu, has been prescribed in multiple cities, marking its entry into clinical practice [9] - Fuhong Hanlin completed the first patient dosing in Japan for its drug Hanshuang in a trial for extensive-stage small cell lung cancer [10] Group 4: Corporate Actions - Wantai Biological Pharmacy responded to investor concerns regarding the efficacy data of its 9-valent HPV vaccine, stating that the circulating data is inaccurate [12] - A senior executive at Kew Flower Pharmaceutical resigned due to retirement, effective immediately [13]

Macro Overview - The Federal Reserve paused interest rate cuts in June, maintaining the federal funds rate at 4.25%-4.50% while continuing quantitative tightening, which aligns with market expectations [2][3] - Economic forecasts indicate a downward adjustment in growth expectations for 2025 and 2026, with unemployment rates slightly increased, reflecting concerns over "stagflation" [3][4] - The dollar index is expected to decline further in 2025 due to tariffs, economic slowdown, and strengthening of alternative assets, stabilizing below 100 for the year [7] Home Appliances Industry - The home appliance sector is expected to benefit from long-term stability, with white goods focusing on performance consistency and increasing dividend rates, while black goods present opportunities due to enhanced global competitiveness [9][12] - The industry has seen a significant increase in the SW home appliance index, with respective gains of 3.8%, 25.4%, and 1.93% for 2023, 2024, and 2025 YTD [9][10] - The outlook for the home appliance market is cautious due to potential demand exhaustion and intensified competition, particularly in the air conditioning segment [10][11] Chemical Industry - The chemical industry is currently facing significant supply and demand pressures, with low profitability in the petrochemical sector, and a need for structural opportunities as the market stabilizes [15][16] - Brent crude oil prices are projected to range between $60-$70 per barrel in the second half of 2025, which may alleviate some cost pressures for the industry [15] - Key investment themes include domestic demand stimulation, supply-side constraints, and the domestic substitution of new materials [15][16] New Energy Sector - The new energy sector is experiencing structural differentiation, with a focus on new technologies and non-US exports, particularly in the wind and solar energy segments [18][19] - The demand for energy storage is expected to shift from policy-driven to market-driven profitability, with significant growth potential in domestic and overseas markets [20][21] - The wind energy sector is anticipated to see a recovery in profitability, driven by increased installations and demand from emerging markets [19][20] Investment Strategies - The report emphasizes the importance of long-term investment strategies, particularly in state-owned enterprises, technology, and consumer sectors, which are expected to yield stable excess returns [24][25] - The development of public funds is expected to favor long-term and passive investment strategies, with a focus on ETFs and sector-specific funds [25][26] - The report highlights the potential for significant returns through quantitative stock selection strategies based on fundamental factors [24][26]

Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1][17]. Core Viewpoints - The new materials sector is a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to enter a phase of accelerated long-term growth. The report emphasizes that "one generation of materials supports one generation of industry," highlighting the foundational nature of the new materials industry as the material basis for other industries [4][17]. Summary by Sections 1. New Materials Industry Dynamics 1.1 Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [5]. - The global first AI-based processor chip design system "Enlightenment" was recently launched, achieving full automation in chip design, with significant performance metrics surpassing human-designed levels [6][24]. 1.2 Aerospace Sector - Key areas of interest include PI films, precision ceramics, and carbon fibers [7]. 1.3 New Energy Sector - Focus on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [9]. - The International Energy Agency (IEA) predicts a 70% increase in global investment in clean hydrogen compared to 2024, with total spending expected to reach approximately $7.8 billion in 2025 [10]. 1.4 Biotechnology Sector - Key areas include synthetic biology and scientific services [11]. 1.5 Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics [13]. 2. Key Companies and Profit Forecasts - The report lists several key companies with their respective stock prices and earnings per share (EPS) forecasts for 2024 to 2026, indicating a positive outlook for many companies in the new materials sector [16].

图片来源：华鑫新材 据悉，时代华鑫成立于2019年，原为中车时代新材产品事业部，现为混改股份制企业，公司主要股东有华舆国创、中车时代新材、中国国调基金、国 开制造转型、国投创业、民生基金、湖南高新、达晨财智等，是国家级专精特新"小巨人"企业。公司主要从事 高性能聚酰亚胺薄膜 等相关高分子材料 的研究和开发及生产 ，2017年建成了 国内首条化学亚胺法PI薄膜生产线 ，成功实现了 化学亚胺制膜规模化量产和商品化 。产品广泛应用于苹果、三 星、华为、荣耀、OPPO、VIVO、小米、Google和亚马逊等国内外著名公司。 产品方面： 时代华鑫目前在透明聚酰亚胺薄膜、耐电晕聚酰亚胺薄膜、超尺寸稳定型聚酰亚胺薄膜（IC封装）、普通稳定型聚酰亚胺薄膜（FPC）、 导热石墨用聚酰亚胺薄膜均有相关布局。值得一提的是，时代华鑫是 全球首家开发出90微米以上超厚型导热石墨原膜 的企业，可应用于50微米以上高 热通量导热石墨片的制备。 产能方面： 时代华鑫现有产线2条，另有规划建设产线1条，远期规划产线1条，一号、二号产线已投产， 产能合计约1,200吨 ;三号产线正在规划建设 中，产能约900吨;四号产线为远期规划产线，产能约1 ...

Group 1 - Specialty plastics are key materials supporting high-end manufacturing, new energy, and aerospace industries, with a global market size of 94 billion yuan in 2022 and a compound annual growth rate (CAGR) of 9.58% from 2018 to 2022 [2][8] - The Chinese specialty engineering plastics market reached 13.5 billion yuan in the same period, accounting for 14% of the global market, but the self-sufficiency rate was only 36% in 2021 [8] - Major types of specialty plastics include polycarbonate, specialty polyamide, polyimide, polyether ether ketone (PEEK), and polysulfone [2][8] Group 2 - PEEK material exhibits excellent high-temperature resistance, chemical corrosion resistance, high strength, rigidity, and good dimensional stability, making it ideal for high-end manufacturing applications, including humanoid robots [3][12] - The long-term usage temperature of PEEK can reach 260°C, with short-term usage temperatures exceeding 300°C, maintaining good mechanical properties even in high-temperature environments [3][9] - PEEK's production involves high barriers due to its complex manufacturing process, which includes multiple steps and requires precise control of temperature and pressure [15][13] Group 3 - PI (polyimide) is recognized for its excellent flame retardancy, electrical insulation, mechanical properties, and chemical stability, making it one of the most promising engineering plastics of the 21st century [4][35] - The global flexible sensor market is projected to reach 6.51 billion USD in 2024, with expectations of explosive demand driven by the rapid development of the robotics industry [4][35] - The supply of high-end polyimide is currently dominated by foreign companies, with domestic manufacturers focusing mainly on lower-end products [44][35] Group 4 - The humanoid robot market in China is estimated to be between 2 to 5 billion yuan, with projections suggesting it could grow to 50 to 500 billion yuan by 2035 [27][28] - PEEK material is expected to replace certain structural components in humanoid robots, with a potential value contribution of approximately 1,367 to 4,102 yuan per robot [25][24] - The competition in the PEEK market is intensifying, with international companies currently leading but domestic firms rapidly advancing in technology and market share [28][31]

Core Viewpoint - Hecotech Pharmaceuticals has received approval for its core product, Deutetrabenazine capsules, marking the company's first commercialized product after years of operating with zero drug revenue [2][3]. Group 1: Product Approval and Market Potential - Deutetrabenazine capsules are approved for treating metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have not previously received novel androgen receptor inhibitors [3]. - The drug is the first deuterated mechanism innovation in the prostate cancer field and the first domestic innovative drug approved for this indication [3]. - According to GLOBOCAN 2022, there were 1.467 million new prostate cancer cases globally in 2022, with 134,000 new cases reported in China [3]. Group 2: Company Financials and Historical Context - Prior to the approval of Deutetrabenazine, Hecotech Pharmaceuticals had maintained a "zero drug revenue" status, resulting in cumulative losses of 1.703 billion yuan from 2019 to 2024 [4]. - The company is accelerating its commercialization process and has established a GMP-compliant R&D production base in Chengdu, along with a professional marketing team [4]. Group 3: Competitive Landscape - Deutetrabenazine is a deuterated version of enzalutamide, which was originally developed by Astellas and Medivation and has generated over $4 billion in global sales by 2019 [5]. - Enzalutamide's sales reached $5.67 billion in 2024, making it a significant revenue source for Astellas [5]. - Several domestic companies have developed generic versions of enzalutamide, with competition expected to intensify as the patent expires in 2026 [5].